FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386056853> ?p ?o ?g. }

• W4386056853 endingPage "123345" @default.
• W4386056853 startingPage "123345" @default.
• W4386056853 abstract "The nasal route has been investigated as a promising alternative for drug delivery to the central nervous system, avoiding passage through the blood-brain barrier and improving bioavailability. In this sense, it is necessary to develop and test the effectiveness of new formulations proposed for the management of neurological disorders. Thereby, the aim of this work was to develop and characterize an ion sensitive in situ hydrogel containing diazepam-loaded nanostructured lipid carriers (DZP-NLC) for nasal delivery in the treatment of epilepsy. Physical characterization of the developed formulations was performed and included the evaluation of rheological features, particle size, polydispersity index (PDI) and zeta potential (ZP) of an in situ hydrogel containing DZP-NLC. Afterwards, in vitro drug release, in vitro mucoadhesion and biocompatibility studies with RPMI 2650 nasal cells were performed. The in situ hydrogel containing DZP-NLC was aerosolized with a nasal spray device specifically designed for nose-to-brain delivery (VP7 multidose spray pump with a 232 N2B actuator) and characterized for droplet size distribution and spray cone angle. Finally, the deposition pattern of this hydrogel was evaluated in a 3D-printed human nasal cavity model. The developed in situ hydrogel containing DZP-NLC presented adequate characteristics for nasal administration, including good gelling ability, mucoadhesiveness and prolonged drug release. In addition, after inclusion in the hydrogel net, the particle size (81.79 ± 0.53 nm), PDI (0.21 ± 0.10) and ZP (-30.90 ± 0.10 mV), of the DZP-NLC remained appropriate for nose-to-brain delivery. Upon aerosolization in a nasal spray device, a suitable spray cone angle (22.5 ± 0.2°) and adequate droplet size distribution (Dv (90) of 317.77 ± 44.12 µm) were observed. Biocompatibility studies have shown that the developed formulation is safe towards RPMI 2650 cells in concentrations up to 100 μg/mL. Deposition studies on a 3D-printed human nasal cavity model revealed that the best nasal deposition profile was obtained upon formulation administration without airflow and at an angle from horizontal plane of 75°, resulting in 47% of administered dose deposited in the olfactory region and 89% recovery. The results of this study suggested that the intranasal administration of the developed in situ hydrogel containing DZP-NLC could be a promising alternative to the conventional treatments for epilepsy." @default.
• W4386056853 created "2023-08-23" @default.
• W4386056853 creator A5007717519 @default.
• W4386056853 creator A5012242755 @default.
• W4386056853 creator A5017206145 @default.
• W4386056853 creator A5042166570 @default.
• W4386056853 creator A5063192974 @default.
• W4386056853 creator A5076750719 @default.
• W4386056853 creator A5078231774 @default.
• W4386056853 creator A5080222954 @default.
• W4386056853 creator A5088443503 @default.
• W4386056853 date "2023-09-01" @default.
• W4386056853 modified "2023-10-16" @default.
• W4386056853 title "In situ hydrogel containing diazepam-loaded nanostructured lipid carriers (DZP-NLC) for nose-to-brain delivery: development, characterization and deposition studies in a 3D-printed human nasal cavity model" @default.
• W4386056853 cites W1964066906 @default.
• W4386056853 cites W1973350017 @default.
• W4386056853 cites W1976295364 @default.
• W4386056853 cites W1999049591 @default.
• W4386056853 cites W2009841111 @default.
• W4386056853 cites W2045670750 @default.
• W4386056853 cites W2046692960 @default.
• W4386056853 cites W2049626483 @default.
• W4386056853 cites W2052657306 @default.
• W4386056853 cites W2055733797 @default.
• W4386056853 cites W2058525694 @default.
• W4386056853 cites W2073182697 @default.
• W4386056853 cites W2079407952 @default.
• W4386056853 cites W2088592669 @default.
• W4386056853 cites W2093915810 @default.
• W4386056853 cites W2095588336 @default.
• W4386056853 cites W2096598503 @default.
• W4386056853 cites W2107137470 @default.
• W4386056853 cites W2139518229 @default.
• W4386056853 cites W2193863667 @default.
• W4386056853 cites W2259583233 @default.
• W4386056853 cites W2289520509 @default.
• W4386056853 cites W2332890812 @default.
• W4386056853 cites W2335860919 @default.
• W4386056853 cites W2581449215 @default.
• W4386056853 cites W2621115059 @default.
• W4386056853 cites W2621316425 @default.
• W4386056853 cites W2750980441 @default.
• W4386056853 cites W2789461067 @default.
• W4386056853 cites W2792113920 @default.
• W4386056853 cites W2792959304 @default.
• W4386056853 cites W2802545865 @default.
• W4386056853 cites W2808184515 @default.
• W4386056853 cites W2809795417 @default.
• W4386056853 cites W2889112706 @default.
• W4386056853 cites W2908110420 @default.
• W4386056853 cites W2914507829 @default.
• W4386056853 cites W2916042835 @default.
• W4386056853 cites W2927987729 @default.
• W4386056853 cites W2930083558 @default.
• W4386056853 cites W2954299954 @default.
• W4386056853 cites W2969552420 @default.
• W4386056853 cites W2972061763 @default.
• W4386056853 cites W2982269477 @default.
• W4386056853 cites W2993426547 @default.
• W4386056853 cites W2998319440 @default.
• W4386056853 cites W3009989984 @default.
• W4386056853 cites W3010030860 @default.
• W4386056853 cites W3012425775 @default.
• W4386056853 cites W3016121249 @default.
• W4386056853 cites W3017000841 @default.
• W4386056853 cites W3023014688 @default.
• W4386056853 cites W3027910288 @default.
• W4386056853 cites W3035986373 @default.
• W4386056853 cites W3037874935 @default.
• W4386056853 cites W3043072781 @default.
• W4386056853 cites W3044719830 @default.
• W4386056853 cites W3045112543 @default.
• W4386056853 cites W3046258544 @default.
• W4386056853 cites W3046874349 @default.
• W4386056853 cites W3048651705 @default.
• W4386056853 cites W3086138357 @default.
• W4386056853 cites W3088014179 @default.
• W4386056853 cites W3102792475 @default.
• W4386056853 cites W3108916145 @default.
• W4386056853 cites W3112659503 @default.
• W4386056853 cites W3113261592 @default.
• W4386056853 cites W3118257616 @default.
• W4386056853 cites W3138364107 @default.
• W4386056853 cites W3165874655 @default.
• W4386056853 cites W3170620880 @default.
• W4386056853 cites W3175526367 @default.
• W4386056853 cites W3177563078 @default.
• W4386056853 cites W3183987128 @default.
• W4386056853 cites W3184410654 @default.
• W4386056853 cites W3205000217 @default.
• W4386056853 cites W3213164825 @default.
• W4386056853 cites W4223474168 @default.
• W4386056853 cites W4379536349 @default.
• W4386056853 cites W3184682479 @default.
• W4386056853 doi "https://doi.org/10.1016/j.ijpharm.2023.123345" @default.
• W4386056853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37619806" @default.
• W4386056853 hasPublicationYear "2023" @default.
• W4386056853 type Work @default.

• next